Details of the Drug Combinations

General Information of This Drug (ID: DMBHMOX)

• Drug Name: Palonosetron (DMBHMOX)
• Synonyms: Aloxi; Onicit; Palonosetron [INN]; Aloxi (TN); RS 25233-197; RS 25259-197; RS-25233-197; RS-25259-197; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one

Indication

Nausea; ICD 11: MD90; Status: Approved [1]; Vomiting; ICD 11: MD90; Status: Approved [2]

• Therapeutic Class: Antiemetics
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

47 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Acetohydroxamic Acid + Palonosetron	DCQM1MR	Acetohydroxamic Acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Arfolitixorin + Palonosetron	DCB687U	Arfolitixorin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Bortezomib + Palonosetron	DCGCC6T	Bortezomib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Brincidofovir + Palonosetron	DCJZTG1	Brincidofovir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Buspirone + Palonosetron	DC90U5Y	Buspirone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Ciprofibrate + Palonosetron	DC1A0WG	Ciprofibrate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Cytarabine + Palonosetron	DCVQN63	Cytarabine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Docetaxel + Palonosetron	DCN91PG	Docetaxel	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Emetine + Palonosetron	DCINW0Z	Emetine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Epinephrine + Palonosetron	DCAG0NE	Epinephrine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Fenoprofen + Palonosetron	DC9SHRI	Fenoprofen	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Gefitinib + Palonosetron	DCNMHRC	Gefitinib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Hydralazine + Palonosetron	DC7KRVI	Hydralazine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Mecamylamine + Palonosetron	DCL9CVR	Mecamylamine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Mefloquine + Palonosetron	DCUCK4T	Mefloquine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Mycophenolic acid + Palonosetron	DC80AWO	Mycophenolic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Mebutamate	DCDLFIX	Mebutamate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Citalopram	DCIWAYE	Citalopram	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Miglustat	DC3Z9WO	Miglustat	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Vinblastine	DCM2J5V	Vinblastine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Anamorelin	DC6XQ6L	Anamorelin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Metyrosine	DCIKERB	Metyrosine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Pentamidine	DC944QS	Pentamidine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Trazodone	DCBS9HV	Trazodone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Imatinib	DCT2PGM	Imatinib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Oxyphenbutazone	DCVGGMS	Oxyphenbutazone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Brincidofovir	DCEUGT3	Brincidofovir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Hyodeoxycholic acid	DCKI246	Hyodeoxycholic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Mycophenolic acid	DCEJ3JK	Mycophenolic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Doxorubicin	DCU53ER	Doxorubicin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Palonosetron + Olmesartan medoxomil	DCDDD14	Olmesartan medoxomil	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Paromomycin + Palonosetron	DCGHGBR	Paromomycin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Pazopanib + Palonosetron	DCFERFW	Pazopanib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Pinacidil + Palonosetron	DCM11VL	Pinacidil	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
PMID28460551-Compound-2 + Palonosetron	DC6N0QP	PMID28460551-Compound-2	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Primidone + Palonosetron	DCM1Q48	Primidone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Probenecid + Palonosetron	DCG2L50	Probenecid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Pyrazinamide + Palonosetron	DCGGMB2	Pyrazinamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Quinine + Palonosetron	DCR52N8	Quinine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Sitagliptin + Palonosetron	DCZG0DO	Sitagliptin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Sumatriptan + Palonosetron	DCNGMWW	Sumatriptan	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Tamoxifen + Palonosetron	DCFBEGU	Tamoxifen	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Tolvaptan + Palonosetron	DC6J8R5	Tolvaptan	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Topotecan + Palonosetron	DCB8YN5	Topotecan	Chronic myelogenous leukemia (Cell Line: KBM-7)	[4]
Triamterene + Palonosetron	DCPDYR3	Triamterene	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Vorinostat + Palonosetron	DCH2RFE	Vorinostat	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
WAY-100635 + Palonosetron	DC1XBY0	WAY-100635	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]

13 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Aprepitant + Palonosetron	DCMQ9DD	Aprepitant	Leukemia	[5]
Aprepitant + Palonosetron	DCP2LMK	Aprepitant	Postoperative Nausea and Vomiting	[6]
Dexamethasone + Palonosetron	DCRQXDW	Dexamethasone	Chemotherapy-Induced Nausea and Vomiting	[7]
Palonosetron + Hydroxyzine	DC28PA2	Hydroxyzine	Substance-Related Disorders	[8]
Palonosetron + Olanzapine	DCIMDV2	Olanzapine	Chemotherapy-induced Nausea and Vomiting	[9]
Palonosetron + Netupitant	DCN6O9G	Netupitant	Chemotherapy-induced nausea	[10]
Dexamethasone + Palonosetron	DCFHKM0	Dexamethasone	Chemotherapy-induced Nausea and Vomiting	[11]
Dexamethasone + Palonosetron	DC4BZXM	Dexamethasone	Chemotherapy-Induced Nausea and Vomiting	[12]
Palonosetron + Netupitant	DCUR6PZ	Netupitant	Nausea Post Chemotherapy	[13]
Palonosetron + Netupitant	DCSPE9V	Netupitant	Chemotherapy-induced Nausea and Vomiting (CINV)	[14]
Dexamethasone + Palonosetron	DCPZ6UH	Dexamethasone	Postoperative Nausea and Vomiting	[15]
Palonosetron + Propofol	DCV4BOD	Propofol	PONV	[16]
Palonosetron + Ondansetron	DCEKEYS	Ondansetron	PONV	[17]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7486).
• [2] Palonosetron FDA Label
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [5] ClinicalTrials.gov (NCT00415103) AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
• [6] ClinicalTrials.gov (NCT02597907) Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant
• [7] ClinicalTrials.gov (NCT01339260) An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
• [8] ClinicalTrials.gov (NCT00661674) Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
• [9] ClinicalTrials.gov (NCT02970643) Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN
• [10] A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014 Jul;25(7):1333-9.
• [11] ClinicalTrials.gov (NCT01370408) Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
• [12] ClinicalTrials.gov (NCT02445872) Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
• [13] ClinicalTrials.gov (NCT04669132) Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer
• [14] ClinicalTrials.gov (NCT03204279) PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
• [15] ClinicalTrials.gov (NCT02635828) Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis
• [16] ClinicalTrials.gov (NCT02809378) The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of PONV
• [17] ClinicalTrials.gov (NCT02468323) Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia